Products
Online Inquiry
JANEX-1
Cat. No.:
0225LY-1358
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
JANEX-1 functions as a cell-permeable and reversible ATP-competitive inhibitor with high selectivity for JAK3 (IC50: 78 uM), exhibiting minimal impact on SRC tyrosine kinases, Zap/Syk, or JAK1/2.
Synonym:
Jak3 inhibitor I; WHI-P131; 202475-60-3; Janex 1; 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; 4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol; 4-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-; 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-phenol; 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline; 4-(4-hydroxyanilino)-6,7-dimethoxyquinazoline; 4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenol
CAS No.:
202475-60-3
Compound CID:
3794
Formula:
C16H15N3O3
Formula Weight:
297.31
Specification
Targets&IC50:
JAK3: 78 μM
Relative Density:
1.336 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
JANEX-1 can be used in kinase signaling research to explore the potent inhibition of JAK3 and its impact on leukemic cells.
Library Information
Target:
JAK3
Receptor:
JAK3
Pathways:
JAK/STAT signaling; Stem cell regulation; Angiogenesis; Chromatin/Epigenetic
Plate Number:
AOCL-18
Plate Location:
d8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
55 mg/mL; 184.99 mM
ALogP:
3.202
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
4
